Efavirenz + Zidovudine/Lamivudine — Competitive Intelligence Brief

Efavirenz + Zidovudine/Lamivudine (Efavirenz + Zidovudine/Lamivudine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NNRTI + 2 NRTIs). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination therapy (NNRTI + 2 NRTIs) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Efavirenz + Zidovudine/Lamivudine (Efavirenz + Zidovudine/Lamivudine) — ViiV Healthcare. This combination uses a non-nucleoside reverse transcriptase inhibitor (efavirenz) plus two nucleoside reverse transcriptase inhibitors (zidovudine and lamivudine) to block HIV replication at multiple steps.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Efavirenz + Zidovudine/Lamivudine TARGET	Efavirenz + Zidovudine/Lamivudine	ViiV Healthcare	phase 3	Antiretroviral combination therapy (NNRTI + 2 NRTIs)	HIV reverse transcriptase
Multiple Product PrEP Program	Multiple Product PrEP Program	University of Alabama at Birmingham	marketed	Antiretroviral combination therapy (nucleoside/nucleotide reverse transcriptase inhibitors)	HIV reverse transcriptase, HIV integrase
Nevirapine, FTC, and Tenofovir	Nevirapine, FTC, and Tenofovir	University of Maryland, Baltimore	marketed	Antiretroviral combination (NNRTI + NRTI + NtRI)	HIV reverse transcriptase, HIV integrase
Bictegravir, emtricitabine, and tenofovir alafenamide	Bictegravir, emtricitabine, and tenofovir alafenamide	CAN Community Health	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Tenofovir + emtricitabine + lopinavir/ritonavir	Tenofovir + emtricitabine + lopinavir/ritonavir	Juan A. Arnaiz	marketed	Antiretroviral combination (NRTI + protease inhibitor)	HIV reverse transcriptase, HIV protease
Tenofovir alafenamide/emtricitabine	Tenofovir alafenamide/emtricitabine	ViiV Healthcare	marketed	Nucleotide/nucleoside reverse transcriptase inhibitor combination	HIV reverse transcriptase
TAF/FTC FDC	TAF/FTC FDC	Janssen Scientific Affairs, LLC	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NNRTI + 2 NRTIs) class)

1. Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · 1 drug in this class
2. Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
3. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
4. ViiV Healthcare · 1 drug in this class